ALT - Company ID 0001326190
Altimmune, Inc. trades as ALT. In its fiscal 2025 annual report the company posted revenue of $41.00K, up 105.0% from the prior year and net income of -$88.09M. This page tracks Altimmune, Inc. through 981 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years Altimmune, Inc.'s revenue declined from $3.24M to $41.00K, a compound annual decline rate of 38.5%. Net profit margin compressed from -342.6% to -214861.0% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| Employee stock plan | S-8 | 2026-05-13 |
| Quarterly report | 10-Q | 2026-05-13 |
| Major company event | 8-K | 2026-05-13 |
| SCHEDULE 13G | - | 2026-05-12 |
| Insider trade | 4 | 2026-05-01 |
| Insider trade | 4 | 2026-05-01 |
| Insider trade | 4 | 2026-05-01 |
The largest companies sharing Altimmune, Inc.'s SEC industry classification (pharmaceutical preparations).
Altimmune, Inc. reported revenue of $41.00K for fiscal year 2025, an increase of 105.0% year over year.
In its latest fiscal year Altimmune, Inc. reported a net loss of $88.09M.